Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

Trial Details

NCT ID

NCT06928389

Phase

PHASE3

Sponsor

Akeso

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Ivonescimab, docetaxel
Placebo, docetaxel

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
Age ≥ 18 years old and ≤ 75 years old at the time of randomization.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Expected life expectancy of at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →